Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 3, 2013, Pages 112-117

  Kreatsoulas, Catherine ^a   Anand, Sonia S ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Cardiovascular disease; Chronic disease; Hormone replacement therapy; Menopause

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROFEM; ESTROGEN; GESTAGEN; PROGESTERONE;

CANCER MORTALITY; CHRONIC DISEASE; ESTROGEN THERAPY; FOLLOW UP; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); POSTMENOPAUSE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84877246313     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1625     Document Type: Review

References (42)

1. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006; 47 (3 Suppl): S4-S20.
2. Wilson R. Feminine forever. New York: Evans; 1966.
3. Kannel WB, Castelli W P. The Framingham study of coronary disease in women. Med Times. 1972; 100: 173-175.
4. Lacassagne A. The Relation Between Hormones and Cancer. Can Med Assoc J. 1937; 37: 112-117.
5. Krieger N, Löwy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health. 2005; 59: 740-748.
6. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991; 20: 47-63.
7. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280: 605-613.
8. Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
9. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002; 288: 872-881
10. Gompel A, Barlow D, Rozenberg S, Skouby SO; EMAS Executive Committee. The EMAS 2006/2007 update on clinical recommendations on postmenopausal hormone therapy. Maturitas. 2007; 56: 227-229.
11. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med. 2012; 157: 104-113.
12. Agency EM. Guideline on Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Deficiency Symptoms in Postmenopausal women. 2005. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003348.pdf. Accessed January 23, 2013.
13. Administration UFaD. Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women. 2010. http://www.fda.gov/Drugs/DrugSafety/ InformationbyDrugClass/ucm135318.htm. Accessed January 13, 2013.
14. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012; 345: e6409.
15. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Trial does not change the conclusions of Cochrane review of long term hormone therapy for perimenopausal and postmenopausal women. BMJ. 2012; 345: e8141.
16. Anderson GL, Limacher M, Assaf AR, et al.; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-1712.
17. Espeland MA, Rapp SR, Shumaker SA, et al.; Women's Health Initiative Steering Committee. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004; 291: 2959-2968.
18. Rapp SR, Espeland MA, Shumaker SA, et al.; WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 2663-2672.
19. Shumaker SA, Legault C, Kuller L, et al.; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004; 291: 2947-2958.
20. Espeland MA, Brunner RL, Hogan PE, et al. Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. J Am Geriatr Soc. 2010; 58: 1263-1271.
21. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006; 91: 1802-1810.
22. Resnick SM, Espeland MA, An Y, et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab. 2009; 94: 4152-4161.
23. Tierney MC, Oh P, Moineddin R, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology. 2009; 34: 1065-1074.
24. Grady D, Applegate W, Bush T, et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998; 19: 314-335.
25. Grady D, Yaffe K, Kristof M, et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med. 2002; 113: 543-548.
26. Grady D, Herrington D, Bittner V, et al.; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 49-57.
27. Hulley S, Furberg C, Barrett-Connor E, et al.; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 58-66.
28. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003; 138: 1-9.
29. Steinauer JE, Waetjen LE, Vittinghoff E, et al. Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol. 2005; 106: 940-945.
30. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002; 360: 2001-2008.
31. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004; 104: 443-451.
32. Johnson SR, Ettinger B, Macer JL, et al. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol. 2005; 105: 779-787.
33. Waetjen LE, Brown JS, Vittinghoff E, et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstet Gynecol. 2005; 106: 946-952.
34. Vickers MR, Martin J, Meade TW. The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health. 2007; 7: 2.
35. Skouby SO, Al-Azzawi F, Barlow D, et al.; European Menopause and Andropause Society. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas. 2005; 51: 8-14.
36. Gompel A, Rozenberg S, Barlow DH; EMAS board members. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas. 2008; 61: 227-232.
37. Sturdee DW, Pines A, Archer D F, et al.; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011; 14: 302-320.
38. Kreatsoulas C, Anand S. Considering race/ethnicity and socio-economic status in randomized controlled trials. A commentary on Frampton et al.'s systematic review generalizing trial findings and tackling health disparities in asthma research. Soc Sci Med. 2009; 69: 1155-1156.
39. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005; 365: 176-186.
40. Moyer VA.; U.S. Preventive Services Task Force. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012. doi: 10.7326/0003-4819-158-1-201 301 010-00 553. [Epub ahead of print].
41. Zbuk K, Anand SS. Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health. 2012; 66: 1-7.
42. Chlebowski RT, Anderson GL. Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012; 104: 517-527.